Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukemic cells obtained from patients resistant to Imatinib
 

[<<Previous]

[ <<To the list of publications ]

[ Next>> ]

Leukemia 2005, 19, 132-134.

Piazza R, Magistroni V, Gasser Mm Andreoni F, Galietta A, Scapozza L, Gambacorti-Passerini C.

TO THE EDITOR

In this report, we present our experience with 20 patients affected by chronic myelogenous leukaemia (CML) in blast crisis (BC)/accelerated phase (AP) or by Ph+ acute lymphoblastic leukaemia (ALL) treated with Imatinib and in whom resistance to the drug (defined as the inability to maintain a haematological response or as the progression to BC for patients who were in AP at the start of the treatment) developed. These patients were enrolled in registrative or not registrative trials of Imatinib as monotherapy.

Full article available at www.nature.com >>
Full article >> (Pdf, 161 KB)

 

[<<Previous]

[ <<To the list of publications ]

[ Next>> ]